Advertisement

Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response

  • Wael A. AlJaroudiEmail author
  • M. C. Alraies
  • Manuel D. Cerquiera
  • Wael A. Jaber
Original Article

Abstract

Purpose

The safety of regadenoson (Reg) during low-level exercise testing has been established. However, its administration at peak exercise for patients who do not reach target heart rate (THR) on standard exercise treadmill stress testing (ETT) needs to be established, particularly among patients with known coronary artery disease (CAD)

Methods

From our stress myocardial perfusion imaging (MPI) database, we identified all patients between 2009 and 2012 who underwent standard ETT and received Reg at peak exercise for failure to reach THR. Hemodynamics, side effects, and adverse events were entered prospectively into the database at the time of testing and were subsequently retrieved for analysis.

Results

There were 514 patients, mean age 60 ± 12 years, 34 % female gender, and 51 % with prior CAD. There were 218 (42 %) and 297 (57 %) patients who underwent standard or modified Bruce and Cornell protocols, respectively, and with a mean exercise time of 5.8 ± 2.1 min. The mean percentage of peak heart rate achieved was 71 ± 8 %, and mean maximal metabolic equivalent (MET) was 6.7 ± 1.8. There were 63 (12 %) patients who developed ≥30 mmHg drop in systolic blood pressure (SBP) after 2 min of Reg administration, and 10 (2 %) had SBP <100 mmHg at 2 min and were younger and achieved higher METs; 8 and 2 patients were symptomatic, respectively. The most common side effects reported were shortness of breath (12 %), chest pain/discomfort (13 %), and dizziness (7 %). There was one syncopal event, but no high-degree heart block, cardiac or respiratory arrest. Four patients received aminophylline. Women were more likely to have shortness of breath or gastrointestinal symptoms, while diabetics were less likely to have chest discomfort. There was otherwise no significant difference in adverse events between different groups including those with and without CAD.

Conclusion

Among patients undergoing standard treadmill stress testing for MPI who do not reach THR, the administration of Reg at peak exercise is safe and without major adverse events. Future large prospective studies are warranted to further evaluate the off-label use of Reg in this setting.

Keywords

Regadenoson Exercise stress testing Safety 

Notes

Conflicts of interest

The study received no funding. We will be discussing off-label use of regadenoson at peak exercise stress testing. Dr. Manuel Cerquiera is a consultant and a speaker on the Bureau of Astellas®.

References

  1. 1.
    Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J 1973;85:546–62.PubMedCrossRefGoogle Scholar
  2. 2.
    Mark DB, Shaw L, Harrell Jr FE, Hlatky MA, Lee KL, Bengtson JR, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991;325:849–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Jolly MA, Brennan DM, Cho L. Impact of exercise on heart rate recovery. Circulation 2011;124:1520–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999;341:1351–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Iskandrian AS, Heo J, Kong B, Lyons E. Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: analysis of 461 patients. J Am Coll Cardiol 1989;14:1477–86.PubMedCrossRefGoogle Scholar
  6. 6.
    Verzijlbergen JF, Vermeersch PH, Laarman GJ, Ascoop CA. Inadequate exercise leads to suboptimal imaging. Thallium-201 myocardial perfusion imaging after dipyridamole combined with low-level exercise unmasks ischemia in symptomatic patients with non-diagnostic thallium-201 scans who exercise submaximally. J Nucl Med 1991;32:2071–8.PubMedGoogle Scholar
  7. 7.
    Manganelli F, Spadafora M, Varrella P, Peluso G, Sauro R, Di Lorenzo E, et al. Addition of atropine to submaximal exercise stress testing in patients evaluated for suspected ischaemia with SPECT imaging: a randomized, placebo-controlled trial. Eur J Nucl Med Mol Imaging 2011;38:245–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Al Jaroudi W, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol 2009;54:1123–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Leaker BR, O’Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008;15:329–36.PubMedCrossRefGoogle Scholar
  10. 10.
    Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2012;19:681–92.PubMedCrossRefGoogle Scholar
  11. 11.
    Husain Z, Palani G, Cabrera R, Karthikeyan AS, Dhanalakota S, Pathmanathan S, et al. Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. Int J Cardiovasc Imaging 2012;28:1841–9.Google Scholar
  12. 12.
    Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008;15:319–28.PubMedCrossRefGoogle Scholar
  13. 13.
    Aljaroudi W, Hermann D, Hage F, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage renal disease. Am J Cardiol 2010;105:133–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Aljaroudi W, Iqbal F, Koneru J, Bhambhvani P, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage liver disease. J Nucl Cardiol 2011;18:90–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Kwon DH, Cerqueira MD, Young R, Houghtaling P, Lieber E, Menon V, et al. Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients. J Nucl Cardiol 2010;17:853–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63–72.PubMedCrossRefGoogle Scholar
  17. 17.
    Partington SL, Lanka V, Hainer J, Blankstein R, Skali H, Forman DE, et al. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test. J Nucl Cardiol 2012;19:970–8.Google Scholar
  18. 18.
    AlJaroudi W, Jaber WA, Cerqueira M. Effect of tracer dose on left ventricular mechanical dyssynchrony indices by phase analysis of gated single photon emission computed tomography myocardial perfusion imaging. J Nucl Cardiol 2012;19:63–72.PubMedCrossRefGoogle Scholar
  19. 19.
    AlJaroudi W, Jaber WA, Grimm R, Marwick T, Cerqueira M. Alternative methods for the assessment of mechanical dyssynchrony by phase analysis of gated single photon emission computed tomography myocardial perfusion imaging. Int J Cardiovasc Imaging 2012;28:1385–94.Google Scholar
  20. 20.
    Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645–58.PubMedCrossRefGoogle Scholar
  21. 21.
    Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307–16.PubMedCrossRefGoogle Scholar
  22. 22.
    Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. Physiol Rev 2008;88:1009–86.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Wael A. AlJaroudi
    • 1
    • 2
    Email author
  • M. C. Alraies
    • 1
  • Manuel D. Cerquiera
    • 1
  • Wael A. Jaber
    • 1
  1. 1.Heart and Vascular Imaging InstituteCleveland ClinicClevelandUSA
  2. 2.Robert and Suzanne Tomsich Department of Cardiovascular MedicineClevelandUSA

Personalised recommendations